Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$1.70 USD
-0.06 (-3.41%)
Updated Apr 25, 2024 04:00 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Xeris Biopharma Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 72 | 122 | 102 | 134 | 76 |
Receivables | 39 | 31 | 17 | 7 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 39 | 25 | 18 | 8 | 2 |
Other Current Assets | 6 | 9 | 5 | 3 | 4 |
Total Current Assets | 156 | 187 | 143 | 152 | 87 |
Net Property & Equipment | 6 | 6 | 7 | 7 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 13 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 133 | 143 | 154 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 1 | 0 | 0 |
Total Assets | 323 | 345 | 304 | 159 | 109 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 5 | 9 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 60 | 65 | 68 | 25 | 21 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20 | 3 | 2 | 0 | 0 |
Total Current Liabilities | 95 | 74 | 79 | 28 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 4 | 12 | 7 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 191 | 187 | 88 | 87 | 58 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 26 | 30 | 4 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 329 | 299 | 209 | 125 | 95 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 610 | 600 | 555 | 371 | 261 |
Retained Earnings | -617 | -555 | -460 | -337 | -246 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -7 | 45 | 95 | 34 | 14 |
Total Liabilities & Shareholder's Equity | 323 | 345 | 304 | 159 | 109 |
Total Common Equity | -7 | 45 | 95 | 34 | 14 |
Shares Outstanding | 138.10 | 135.50 | 66.50 | 48.90 | 27.00 |
Book Value Per Share | -0.05 | 0.33 | 1.43 | 0.69 | 0.53 |
Fiscal Year End for Xeris Biopharma Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 72 | 66 | 81 | 95 |
Receivables | NA | 39 | 46 | 30 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 39 | 38 | 37 | 29 |
Other Current Assets | NA | 6 | 8 | 8 | 11 |
Total Current Assets | NA | 156 | 158 | 156 | 166 |
Net Property & Equipment | NA | 6 | 6 | 7 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 133 | 135 | 138 | 141 |
Deposits & Other Assets | NA | 5 | 5 | 5 | 5 |
Total Assets | NA | 323 | 328 | 329 | 321 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 12 | 12 | 12 | 12 |
Current Portion Long-Term Debt | NA | 0 | 0 | 17 | 15 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 60 | 54 | 48 | 50 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 20 | 19 | 2 | 3 |
Total Current Liabilities | NA | 95 | 87 | 80 | 81 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 3 | 3 | 4 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 191 | 190 | 188 | 188 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 9 | 10 | 9 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 329 | 324 | 315 | 291 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 610 | 608 | 605 | 602 |
Retained Earnings | NA | -617 | -604 | -591 | -572 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -7 | 4 | 14 | 30 |
Total Liabilities & Shareholder's Equity | NA | 323 | 328 | 329 | 321 |
Total Common Equity | 0 | -7 | 4 | 14 | 30 |
Shares Outstanding | 140.40 | 138.10 | 138.00 | 135.50 | 135.50 |
Book Value Per Share | 0.00 | -0.05 | 0.03 | 0.10 | 0.22 |